DK3107568T3 - Formuleringer til indgivelse til tyndtarmen - Google Patents
Formuleringer til indgivelse til tyndtarmen Download PDFInfo
- Publication number
- DK3107568T3 DK3107568T3 DK15752216.0T DK15752216T DK3107568T3 DK 3107568 T3 DK3107568 T3 DK 3107568T3 DK 15752216 T DK15752216 T DK 15752216T DK 3107568 T3 DK3107568 T3 DK 3107568T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulations
- administration
- small intestine
- intestine
- small
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000000813 small intestine Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942386P | 2014-02-20 | 2014-02-20 | |
| PCT/US2015/016921 WO2015127278A1 (en) | 2014-02-20 | 2015-02-20 | Formulations for small intestinal delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3107568T3 true DK3107568T3 (da) | 2024-06-03 |
Family
ID=53879055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15752216.0T DK3107568T3 (da) | 2014-02-20 | 2015-02-20 | Formuleringer til indgivelse til tyndtarmen |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170224805A1 (enExample) |
| EP (2) | EP4353255A3 (enExample) |
| JP (2) | JP6797692B2 (enExample) |
| KR (1) | KR102396817B1 (enExample) |
| CN (1) | CN106255508B (enExample) |
| AU (1) | AU2015218769B2 (enExample) |
| CA (1) | CA2939581C (enExample) |
| DK (1) | DK3107568T3 (enExample) |
| EA (1) | EA033248B1 (enExample) |
| ES (1) | ES2978921T3 (enExample) |
| IL (1) | IL247301B (enExample) |
| SG (1) | SG11201606814RA (enExample) |
| WO (1) | WO2015127278A1 (enExample) |
| ZA (1) | ZA201605787B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2832504T3 (es) | 2015-06-12 | 2021-06-10 | Vaxart Inc | Formulaciones para administración de antígenos de norovirus y rsv en el intestino delgado |
| CA3046019A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| KR20190104051A (ko) * | 2017-01-06 | 2019-09-05 | 스타빌리테크 바이오파마 리미티드 | 바이러스 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152413A (en) * | 1978-08-18 | 1979-05-01 | Chromalloy American Corporation | Oral vaccine for swine dysentery and method of use |
| US4579945A (en) | 1982-04-29 | 1986-04-01 | Ribi Immunochem Research, Inc. | Purification of trehalose dimycolates |
| US4520019A (en) | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| CA2110899C (en) * | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| WO1994015635A1 (en) | 1993-01-11 | 1994-07-21 | Dana-Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
| GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6676935B2 (en) * | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| AU4133397A (en) * | 1996-10-28 | 1998-05-22 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
| AUPO856097A0 (en) * | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| GB9818591D0 (en) * | 1998-08-27 | 1998-10-21 | Danbiosyst Uk | Pharmaceutical composition |
| US7264771B2 (en) | 1999-04-20 | 2007-09-04 | Baxter International Inc. | Method and apparatus for manipulating pre-sterilized components in an active sterile field |
| US6355270B1 (en) * | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
| JP2004504264A (ja) * | 2000-01-07 | 2004-02-12 | ユニバーシティ オブ シンシナティ | Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化 |
| AU2003240978A1 (en) | 2002-05-31 | 2003-12-19 | Genteric, Inc. | Multi-functional polyamines for delivery of biologically-active polynucleotides |
| AU2003262922A1 (en) | 2002-08-30 | 2004-03-19 | Genteric, Inc. | Retroductal salivary gland genetic vaccination |
| GB2407500A (en) * | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Use of microparticles for antigen delivery |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| EA014757B1 (ru) | 2006-02-28 | 2011-02-28 | Вэксарт, Инк. | Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота |
| JP2009298707A (ja) * | 2008-06-11 | 2009-12-24 | Ohara Yakuhin Kogyo Kk | 粒子加工方法 |
| JP2011526888A (ja) * | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 治療薬を標的送達するための経口速溶性薄膜 |
| US20100221329A1 (en) * | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| WO2011026111A1 (en) * | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| DK2477652T3 (en) | 2009-09-16 | 2015-07-20 | Vaxart Inc | Immunization strategy for the prevention of infection H1Ni |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| CN110152000A (zh) * | 2011-03-02 | 2019-08-23 | J·深塔格 | 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物 |
| CA3008794C (en) * | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| EP3549605A1 (en) * | 2012-04-04 | 2019-10-09 | Vaxform LLC | Adjuvant system for oral vaccine administration |
-
2015
- 2015-02-20 CA CA2939581A patent/CA2939581C/en active Active
- 2015-02-20 EP EP24158414.3A patent/EP4353255A3/en not_active Withdrawn
- 2015-02-20 AU AU2015218769A patent/AU2015218769B2/en active Active
- 2015-02-20 EP EP15752216.0A patent/EP3107568B1/en active Active
- 2015-02-20 US US15/120,069 patent/US20170224805A1/en not_active Abandoned
- 2015-02-20 IL IL247301A patent/IL247301B/en unknown
- 2015-02-20 DK DK15752216.0T patent/DK3107568T3/da active
- 2015-02-20 JP JP2016570917A patent/JP6797692B2/ja active Active
- 2015-02-20 WO PCT/US2015/016921 patent/WO2015127278A1/en not_active Ceased
- 2015-02-20 EA EA201691458A patent/EA033248B1/ru not_active IP Right Cessation
- 2015-02-20 SG SG11201606814RA patent/SG11201606814RA/en unknown
- 2015-02-20 CN CN201580015312.2A patent/CN106255508B/zh active Active
- 2015-02-20 KR KR1020167024704A patent/KR102396817B1/ko active Active
- 2015-02-20 ES ES15752216T patent/ES2978921T3/es active Active
-
2016
- 2016-08-19 ZA ZA2016/05787A patent/ZA201605787B/en unknown
-
2020
- 2020-11-18 JP JP2020191383A patent/JP7168633B2/ja active Active
-
2024
- 2024-10-11 US US18/913,437 patent/US20250032602A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4353255A2 (en) | 2024-04-17 |
| EA201691458A1 (ru) | 2017-02-28 |
| CA2939581C (en) | 2024-01-23 |
| EP3107568A4 (en) | 2017-10-11 |
| US20170224805A1 (en) | 2017-08-10 |
| CA2939581A1 (en) | 2015-08-27 |
| AU2015218769B2 (en) | 2020-09-17 |
| IL247301A0 (en) | 2016-09-29 |
| IL247301B (en) | 2022-07-01 |
| EP3107568B1 (en) | 2024-03-27 |
| ZA201605787B (en) | 2017-11-29 |
| ES2978921T3 (es) | 2024-09-23 |
| CN106255508B (zh) | 2020-07-07 |
| JP6797692B2 (ja) | 2020-12-09 |
| JP7168633B2 (ja) | 2022-11-09 |
| SG11201606814RA (en) | 2016-09-29 |
| EA033248B1 (ru) | 2019-09-30 |
| JP2017506265A (ja) | 2017-03-02 |
| KR20170007726A (ko) | 2017-01-20 |
| US20250032602A1 (en) | 2025-01-30 |
| CN106255508A (zh) | 2016-12-21 |
| EP3107568A1 (en) | 2016-12-28 |
| AU2015218769A1 (en) | 2016-09-08 |
| JP2021038243A (ja) | 2021-03-11 |
| WO2015127278A1 (en) | 2015-08-27 |
| KR102396817B1 (ko) | 2022-05-11 |
| EP4353255A3 (en) | 2024-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3236943T3 (da) | Sammensætninger til ileo-jejunal lægemiddeladministration | |
| IL246978A0 (en) | New paracetamol formulations | |
| PL4070788T3 (pl) | Formulacje farmaceutyczne | |
| DK3089741T3 (da) | Farmaceutiske sammensætninger omfattende azd9291 | |
| BR112016023628A2 (pt) | composições farmacêuticas. | |
| IL256491A (en) | Pharmaceutical formulations | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| DK3229816T3 (en) | Proton-bindende polymerer til oral administration | |
| EP3237013C0 (en) | TRANSDERMAL FORMULATIONS | |
| HUE050779T2 (hu) | Folyékony gyógyszerészeti készítmény | |
| ZA201707094B (en) | Pharmaceutical formulations | |
| EP3337463A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| DK3148513T3 (da) | Ceritinib-formulering | |
| DK3107568T3 (da) | Formuleringer til indgivelse til tyndtarmen | |
| DK3193856T3 (da) | Formulering | |
| HUE050881T2 (hu) | Gyógyszerkészítmény | |
| EP3181125C0 (en) | CAPSULE FORMULATION | |
| GB201417589D0 (en) | Pharmaceutical Formulations | |
| TR201503831A2 (tr) | Antimipertansif kombinasyon formülasyonları | |
| EP3134067C0 (en) | VETERINARY COMPOSITION | |
| TH1501007302A (th) | ยาเตรียมทางเภสัชกรรม | |
| TH1601003393A (th) | รูปแบบปริมาณที่ให้ทางเภสัชกรรม | |
| BR112017004882A2 (pt) | composição farmacêutica oral. | |
| TH1501006784A (th) | องค์ประกอบทางเภสัชกรรมขนาดยาต่ำ | |
| ES1114184Y (es) | Estribera Perfeccionada |